5-METHYL-2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL

o-1821 is an cannabidiol analog with similar structure to o-1918, a selective antagonist of abnormal cannabidiol.abnormal cannabidiol, a synthetic regioisomer of cannabidiol, fails to elicit either central cannabinoid (cb1) or peripheral cannabinoid (cb2) receptors and is lack of psychotropic activity. it can induce endothelium-dependent vasodilation through a cb1/cb2/nitric oxide-independent mechanism.

o-1821 is a cannabidiol analog with similar structure to o-1918, which was identified as a selective antagonist of abnormal cannabidiol at the non-central cannabinoid (cb1)/peripheral cannabinoid (cb2) receptors endothelial receptor. it was found that o-1918 could not bind to cb1 or cb2 receptors and thus could not cause vasorelaxation at concentrations up to 30 μm, but it could cause concentration-dependent inhibition of the vasorelaxant effects of abn-cbd and anandamide. moreover, in human umbilical vein endothelial cells, abn-cbd was able to induce phosphorylation of p42/44 mitogenactivated protein kinase and protein kinase b/akt, which could be inhibited by o-1918 or by phosphatidylinositol 3 (pi3) kinase inhibitors [1].

o-1918 was found to be able to inhibit the hypotensive effect of abn-cbd dose-dependently but not the hypotensive effect of the cb1 receptor agonist (-)-11-oh-δ9-tetrahydrocannabinol dimethylheptyl in anesthetized mice [1].

[1] offertáler, l. ,mo, f.m.,bátkai, s., et al. selective ligands and cellular effectors of a g protein-coupled endothelial cannabinoid receptor. molecular pharmacology 63(3), 699-705 (2003).